We are revolutionizing the treatment of Dengue virus infection with our groundbreaking therapy that seamlessly integrates a drug-device system. Our innovative approach harnesses powerful antiviral properties through a unique mechanism, addressing both the viral and host immune response aspects of Dengue infections as follows

At the heart of our therapy is a continuous redox cycling process that dynamically converts our drug between its oxidized and reduced states. This innovative mechanism enhances the drug’s efficacy against the Dengue virus, setting a new standard in antiviral treatment.

WELBLU combines the strengths of a repurposed sub-lingual drug & a non invasive low visible light emitting device creating a hybrid action therapy that significantly amplifies treatment effectiveness.

The technology transforms one drug into two forms:
• Ionic Form (Oxidized State): Specifically targets viral lipid layer of double enveloped RNA virus and inhibits the virus’s ability to replicate.
• Nonionic Form (Reduced State): Drives the redox cycling mechanism, optimizing the host immune response and enhance the overall effectiveness.

In addition to targeting the virus, WELBLU is designed to combat oxidative stress and inflammation in the host body. By addressing these critical complications associated with Dengue infection, we strive to improve patient outcomes and overall health.

We are dedicated to advancing therapeutic solutions that redefine the landscape of Dengue treatment. Our goal is to enhance patient care and strengthen global healthcare ecosystem. Join us in our mission to transform the future of Dengue treatment and improve the lives worldwide.